ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2450

Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts

Maria Filkova1, Michelle Trenkmann1, Borbala Aradi-Vegh1, Lenka Pleštilová1, Joanna Stanczyk1, Beat A. Michel2, Ladislav Senolt3, Renate Gay1, Steffen Gay4 and Astrid Juengel1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, 2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: MicroRNA, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Comprehensive analysis of 260 miRNAs suggested a downregulation of miR-196a in rheumatoid arthritis (RA) synovial fibroblasts (SF) compared with osteoarthritis (OA) SF. Mature miR-196a originates from 2 regions in human genome: MIR-196-A1 (chromosome 17) and MIR-196-A2 (chromosome 12) both located in HOX- gene clusters. The altered expression of miR-196a has been reported in multiple conditions, such as cancer. Our aim is to analyze the expression and regulation of miR-196a in cells from patients with RA.

Methods Expression of pri-miRNA precursor and mature miR-196a was analyzed in RA/OA synovial tissue, SF under proinflammatory and hypoxic conditions, peripheral blood mononuclear cells (PBMC), synovial fluids and sera using TaqMan RealTime-PCR. Chromatin immunoprecipitation (ChIP) was used to analyze histone methylation and acetylation within both promoters MIR-196A1 and MIR-196A2 in SF. Ilumina sequencing with subsequent single assay verification was performed following Lipofectamine transfection with pre-miR-196a or anti-miR-196a to identify miR-196a targets genes. 

Results

Expression of miR-196a is significantly lower in RA synovial tissues (n=6) compared with OA (n=4, p=0.01) as well as RASF (n=19) compared with OASF (n=15, p<0.0001). No difference was observed in PBMC or synovial fluids while a lack of cell-free miR-196a was detected in RA and OA sera. The precursor pri-miR-196A1 was expressed neither in RA nor OA SF while pri-miR-196A2 was significantly downregulated in RASF vs. OASF (n=4 each, p<0.05). Expression of miR-196a in SF was not affected by proinflammatory cytokines (TNFα, IL-1β), TLR ligands (LPS), 1% hypoxia or 5’AZA mediated DNA demethylation. ChIP of MIR-196A2 promoter revealed significantly higher methylation of repressive H3K27me3 (p=0.005), lower methylation of activating H3K4me3 (p=0.001) and hypoacetylation of H3 (p=0.008) in RASF (n=13) compared to OASF (n=10) explaining the downregulation of the mature miR-196a in RASF. Using Ilumina sequencing after pre-miR transfection of RASF (n=2) HOXC8 and HOXA7 were identified as most likely direct miR-196a targets. Downregulation HOXC8 (p=0.01) as well as HOXA7 (p<0.0001) pre-miR-196a transfection (n=5), and upregulation of HOXC8 (p=0.11) and HOXA7 (p=0.56) and upon anti-miR-196a transfection (n=5)  suggest these HOX genes as direct targets. However, unexpectedly,  significant downregulation of HOXC8 was observed in RASF (n=17) vs. OASF (n=18, p=0.004) while the expression HOXA7 was not significantly different between RASF and OASF (p=0.91).

Conclusion

MiR-196a is one of the few miRNA showing a significant dowregulation in resident cells of synovial tissue in RA patients regulated by histone modifications. Although HOXC8 and HOXA7 are suggestive of being direct targets of miR-196a, their distinctive role in unique RASF behavior remains to be investigated.  Given low expression of miR-196a in RASF and location within HOXC cluster, we hypothesize that expression of HOXC8, except regulation by miR-196a, may be influenced by additional epigenetic features similar to those regulating miR-196a.


Disclosure:

M. Filkova,

MHCR no. 23728 ,

2;

M. Trenkmann,
None;

B. Aradi-Vegh,

EuroTEAM,

2;

L. Pleštilová,

OSTEOIMMUNE,

2;

J. Stanczyk,
None;

B. A. Michel,
None;

L. Senolt,

MHCR no 23728,

2;

R. Gay,
None;

S. Gay,
None;

A. Juengel,

IMI BTCure,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/downregulation-of-mirna-196a-and-its-downstream-hoxc8-target-gene-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology